✦ LIBER ✦

A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript

✍ Scribed by Xiaoqing Li; Jing Yang; Xiangjun Chen; Jun Liu; Hongrui Li; Jine Zheng; Yanli He; Zhong Chen; Shiang Huang

Book ID: 113513150
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 429 KB
Volume: 176
Category: Article
ISSN: 0165-4608
DOI: 10.1016/j.cancergencyto.2007.04.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib induces a cytogenetic response

Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts

✍ Lee, J-J; Kim, H-J; Kim, Y-J; Lee, S; Hwang, J-Y; Kim, Y-L; Kim, D-W 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 66 KB

Major molecular response to imatinib in

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript

✍ Tchirkov, A; Couderc, J-L; Périssel, B; Goumy, C; Regnier, A; Uhrhammer, N; Verr 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 94 KB

Complete cytogenetic and molecular respo

Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript

✍ Barbara Pienkowska-Grela; Renata Woroniecka; Iwona Solarska; Kinga Kos; Anna Pas 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 198 KB

Isolated thrombocytosis as first sign of

Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib

✍ Massimo Breccia; Laura Cannella; Daniela Diverio; Paola Streponi; Mauro Nanni; C 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Since very few unusual BCR/ABL fusion transcripts in chronic myeloid leukemia have been reported, no clear evidence exists concerning their clinical and prognostic implications. We describe here a CML case with normal karyotype at standard cytogenetics and an atypical e6a2 BCR/ABL fusion transcript,

Is it possible to discontinue imatinib m

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o

Complete hematologic and cytogenetic res

Complete hematologic and cytogenetic response to 2-amino-9-β-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogeneous leukemia in T-cell blastic phase : A case report and review of the literature

✍ Alvaro Aguayo; Jorge E. Cortes; Hagop M. Kantarjian; Miloslav Beran; Varsha Gand 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## BACKGROUND. T-cell lymphoid blastic phase (BP) transformation is rare in chronic myelogenous leukemia (CML). 2-amino-9-␤-D-arabinosyl-6-methoxy-9H-guanine (GW506U78), a prodrug of arabinosylguanine (ara-G), is effective in T-cell leukemias. ## METHODS. The authors present a case of a 48-year